Intravenous As 2 O 3 as a promising treatment for psoriasis - an experimental study in psoriasis-like mouse model.

Clinical dosage of AsO may achieve effective treatment of IMQ-induced psoriatic skin lesions by modulating the NF-κB signaling pathway which regulates both the RIG-I and the miR-31 lines of action. Our data provided strong evidence supporting the claim that systemic AsO administration of clinical doses can be a promising treatment for psoriasis patients.